Email Us
Call Us
AUSTIN, Texas – June 14, 2014 – Data generated at Altogen Labs appears in the supporting experimental record of an international patent family covering oligonucleotide-based therapeutics for the modulation of disease-associated genes. The filing identifies Altogen Labs as the laboratory that performed the HepG2 cell culture work, the quantitative PCR analysis, and the cell growth inhibition assays across A549 human lung carcinoma, MDA-MB-231 human breast carcinoma, and DU145 human prostate carcinoma cell lines. Among the reported results, a PCSK9-targeted oligonucleotide produced an approximate 40% reduction in PCSK9 mRNA at 72 hours post-exposure in HepG2 cells while showing no cytotoxicity at either 24 or 72 hours — a clean separation of pharmacology from toxicity that only careful assay execution can demonstrate.
Patent-supporting data carries a particular burden. It must withstand examiner scrutiny, and potentially litigation, years after it was generated. Sponsors bring this work to Altogen Labs because the company operates to that standard as a matter of routine: documented protocols, defined passage ranges, quadruplicate treatments, controlled cell densities, and complete raw data delivered to the client.
Altogen Labs supports intellectual property development across its full service portfolio — IC50 and viability screening across more than 100 tumorigenic cell lines, gene expression analysis by RT-PCR, protein quantification by automated capillary Western, stable cell line development, CRISPR/Cas9 editing, RNAi and oligonucleotide delivery, and in vivo efficacy testing in its large collection of validated xenograft models. One hundred percent of intellectual property generated in a study belongs to the client.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research services and biology CRO services to pharmaceutical companies, biotechnology firms, and academic institutions worldwide. The company maintains a large collection of in-house validated xenograft models — CDX, PDX, syngeneic, organoids, and NAMs — and extensive experience in efficacy xenograft studies and safety toxicology studies supporting IND applications, patent filings, and regulatory submissions.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com
Source citation: ProNAi Therapeutics Inc., “DNAi for the modulation of genes,” EP2970965A2 / WO2014144942 (priority date March 15, 2013), states that HepG2 cell culture work, qPCR analysis, and cell growth inhibition assays for A549, MDA-MB-231 and DU145 were performed at Altogen Labs (Austin, TX).